Abstract | BACKGROUND: METHODS: Swiss mice were treated intracerebroventricularly with aggregated Aβ 25-35 peptide and examined after 1 week in a battery of memory tests (spontaneous alternation, passive avoidance, object recognition, place learning in the water-maze, topographic memory in the Hamlet). Toxicity induced in the mouse hippocampus or cortex was analyzed biochemically or morphologically. RESULTS: CONCLUSIONS: FENM therefore appeared as a potent neuroprotective drug in an AD model, with a superior efficacy compared with Memantine and an absence of direct amnesic effect at higher doses. These results open the possibility to use the compound at more relevant dosages than those actually proposed in Memantine treatment for AD.
|
Authors | Simon Couly, Morgane Denus, Mélanie Bouchet, Gilles Rubinstenn, Tangui Maurice |
Journal | The international journal of neuropsychopharmacology
(Int J Neuropsychopharmacol)
Vol. 24
Issue 2
Pg. 142-157
(02 15 2021)
ISSN: 1469-5111 [Electronic] England |
PMID | 32977336
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2020. Published by Oxford University Press on behalf of CINP. |
Chemical References |
- Amyloid beta-Peptides
- Neuroprotective Agents
- Peptide Fragments
- amyloid beta-protein (25-35)
- fluoroethylnormemantine
- Memantine
|
Topics |
- Alzheimer Disease
(chemically induced, drug therapy, prevention & control)
- Amnesia
(chemically induced, drug therapy, prevention & control)
- Amyloid beta-Peptides
(pharmacology)
- Animals
- Behavior, Animal
(drug effects)
- Disease Models, Animal
- Male
- Memantine
(administration & dosage, analogs & derivatives, pharmacology)
- Memory Disorders
(chemically induced, drug therapy)
- Mice
- Mice, Inbred C57BL
- Neuroprotective Agents
(administration & dosage, pharmacology)
- Peptide Fragments
(pharmacology)
|